ALNY - Alnylam maintains bullish views at Street firms following Q4 revenue beat

Several Street firms are maintaining bullish views on Alnylam Pharmaceuticals (ALNY -0.7%) following the biotech's Q4 2021 earnings results Thursday. Piper Sandler's Edward Tenthoff is maintaining his overweight rating and $208 price target (~38% upside based on Thursday's close). He said he is confident that the company will win approval of vutrisiran for hATTR polyneuropathy by the April FDA action date. Morgan Stanley's Matthew Harrison said Alnylam's 2022 guidance is conservative. He has an overweight rating and $215 target (~43% upside). Jefferies Maury Raycroft increased his target to $221 from $205 (~46% upside) while maintaining his buy rating. Read why Seeking Alpha contributor Terry Chrisomalis considers Alnylam a strong buy.

For further details see:

Alnylam maintains bullish views at Street firms following Q4 revenue beat